Secondary acute myelogenous leukemia in patients with retinoblastoma - Is chemotherapy a factor?
Secondary acute myelogenous leukemia in patients with retinoblastoma - Is chemotherapy a factor?
复制标题
DOI：
10.1016/j.ophtha.2007.03.074
复制
发表时间：
2007-07-01
期刊：
影响因子：
13.7
通讯作者：
Yu, Christopher Bing On
中科院分区：
文献类型：
--
作者：
Gombos, Dan S.;Hungerford, John;Yu, Christopher Bing On
目的：描述一系列继发性急性髓性白血病（sAML）合并视网膜母细胞瘤（RB）的患者。设计：回顾性观察病例系列。参与者：欧洲和美洲转诊中心的眼科和儿科肿瘤学家，美国国立卫生研究院和纪念斯隆-凯特琳癌症中心眼科肿瘤学服务的RB数据库。方法：医师调查、回顾性数据库回顾、文献检索。主要观察指标：RB病史和sAML的发展，RB的处理（手术、放疗、化疗），RB和白血病诊断时的年龄，法、美、英（FAB）亚型，患者现状（活或死）。结果：确诊sAML患者15例；13例发生在儿童时期。从RB到AML诊断的平均潜伏期为9.8年（中位数为42个月）。9例为M2或M5 FAB亚型。12名患者（79%）接受了拓扑异构酶II抑制剂化疗，8名患者（43%）接受了表观卟啉毒素化疗。十个孩子死于白血病。结论：急性髓性白血病是视网膜母细胞瘤患者中一种罕见的继发性恶性肿瘤，许多患者接受过原发性或辅助化疗。需要进一步的研究来评估在该队列中导致sAML发展的潜在危险因素。
Purpose: To describe a series of patients with secondary acute myelogenous leukemia (sAML) and retinoblastoma (RB).Design: Retrospective observational cases series.Participants: Ocular and pediatric oncologists at referral centers in Europe and the Americas and the RB databases at the National Institutes of Health and the Ophthalmic Oncology Service at Memorial Sloan-Kettering Cancer Center.Methods: Physician survey, retrospective database review, and literature search.Main Outcome Measures: History of RB and development of sAML, management of RB (surgery, radiotherapy, chemotherapy), age at diagnosis of RB and leukemia, French-American-British (FAB) subtype, and current status of patient (alive or dead).Results: Fifteen patients with sAML were identified; 13 occurred in childhood. Mean latent period from RB to AML diagnosis was 9.8 years (median, 42 months). Nine cases were of the M2 or M5 FAB subtypes. Twelve patients (79%) had received chemotherapy with a topoisomerase II inhibitor, 8 (43%) had received chemotherapy with an epipodophyllotoxin. Ten children died of their leukemia.Conclusions: Acute myelogenous leukemia is a rare secondary malignancy among retinoblastoma patients, many of whom were treated with primary or adjuvant chemotherapy. Additional studies are needed to assess potential risk factors contributing to sAML development in this cohort.